艾迪注射液联合肝动脉介入治疗原发性肝癌的临床研究  

Clinical study on transcatheter arterial chemoembolization and AIDI injection in treatment of primary hepatocellular carcinoma

作　　者：张国顺[1] 张文缓 马利转 张超[1] 王玉兰[1] 李玉林[1] 

机构地区：[1]华北煤炭医学院附属医院消化科,唐山063000 [2]武警河北总队唐山分院

出　　处：《现代预防医学》2012年第5期1253-1255,共3页Modern Preventive Medicine

基　　金：唐山市科技攻关项目(081302010)

摘　　要：目的评价中药艾迪注射液联合肝动脉介入治疗法治疗肝癌的疗效。方法 94例原发性肝癌患者随机分为病例组和对照组,每组各47例。病例组采用艾迪注射液100ml＋0.9%氯化钠溶液500ml静脉点滴,d1-28;静滴同时进行肝动脉介入治疗,药物为羟基喜树碱（HCPT）10mg,氟尿嘧啶（5-Fu）500mg,碘化油10ml,按Seldinger’s技术要求,将药物注入肝脏肿瘤供养血管并行栓塞。28d为1周期。对照组47例单用肝动脉介入治疗方案,同病例组,2个周期后评价。结果病例组和对照组的有效率分别为78.7%和44.7%,中位生存期8.41月和8.17月,平均生存期12.71月和9.23月,半年生存率89.3%和82.9%,1年生存率63.8%和46.8%,2年生存率27.7%和17.0%。全组初治者半年生存率83.1%,1年生存率47.7%,2年生存率18.5%,复治者则分别为96.3%、77.8%、33.3%。AFP治疗后下降者病例组26例有效率为70.2%,对照组17例,有效率为51.5%。结论艾迪注射液能提高肝动脉介入治疗率,改善生存质量,延长生存期,多次治疗能提高疗效。OBJECTIVE To evaluate the efficacy of Aidi injection combined with transcatheter arterial chemoembolization in patients with primary hepatic carcinoma.METHODS The patients with primary hepatic carcinoma（n = 94）were random1y divided into two groups.Patients（n = 47）were treated with intravenous Aidi injection（100 ml in 500 ml 0.9%Nacl）for 28 days（dl-d28）,and combined with transcatheter arterial chemoembolization（HCPT 10 mg,5-Fu 500 mg and iodinate oil 10 ml）for 28 days,according to Seldingers technique.The controls（n = 47）were treated with transcatheter arterial chemoembolization alone;after 2 circles of 28-day treatment,the therapeutic effects were evaluated.RESULTS In Aidi and control groups,the effective rates were 78.7% and 44.7%;the median survival time was 8.41 and 8.17 months,the mean survival time was 12.71 and 9.23 months,the half-a-year survival rate was 89.3% and 82.9%,one-year survival rate was 63.8% and 46.8%,and two-year survival rate was 27.7% and 17.0% respectively.For the initial patients in the two groups,the half-a-year survival rate was 83.1%,one-year survival rate was 47.7%,two-year survival rate was 18.5%;for the retreated patients,the corresponding rates were 96.3%,77.8% and 33.3%.After AFP treatment,the declined rate was 70.2% in 26 patients of Aidi group,and was 51.5% in 17 patients of control group.CONCLUSION Aidi injection can enhance the effects of transcatheter arterial chemoembolization,and improve the life quality of the patients and prolong the survival time in patients with primary hepatic carcinoma.The efficacy can be improved after repeated treatment.

关 键 词：艾迪注射液 动脉介入 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]